Lever
Lifestyle
- Regular aerobic exercise
- Smoking cessation
- Weight management
Blutwerte · Marker
Apolipoprotein A1
ApoA1 · Apo A-I
Lipide & Herz-Kreislauf
- Einheit:
- g/L
- Abbreviation
- ApoA1
Apolipoprotein A1 quantifies the major protein component of HDL particles involved in lipid transport and metabolism.
Reference Ranges
Reference
1.25–1.6g/L
1.25
1.2
1.8
1.6
LowNormalHigh
Reference
Optimal
Unit · g/LApoA1 levels are not significantly affected by fasting status.
Overview
Übersicht
Apolipoprotein A1 (ApoA1) is a major protein component of high-density lipoprotein (HDL) in plasma and plays a crucial role in lipid metabolism. It is primarily responsible for the activation of lecithin-cholesterol acyltransferase (LCAT), an enzyme that converts free cholesterol into cholesteryl ester, a more hydrophobic form of cholesterol that is sequestered into the core of the HDL particle. Clinically, ApoA1 is considered a marker of cardiovascular health, as higher levels are associated with a reduced risk of atherosclerotic cardiovascular disease. Researchers found that ApoA1 levels are not significantly affected by fasting status, making it a reliable marker in both fasting and non-fasting states. In the context of athletic performance and biohacking, ApoA1 is of interest due to its role in cholesterol transport and potential implications for cardiovascular endurance and longevity. Elevated ApoA1 levels are generally considered beneficial, as they reflect efficient reverse cholesterol transport and anti-inflammatory properties. However, researchers observed that in certain pathological conditions, such as liver failure or cryoglobulinemia, ApoA1 levels can be altered, which may confound its interpretation. Additionally, while fasting is not required for ApoA1 measurement, it is important to consider factors such as acute illness or chronic inflammation that could affect levels.
Klinische Bedeutung
Elevated ApoA1 levels are associated with a lower risk of cardiovascular disease, reflecting efficient cholesterol efflux and anti-inflammatory properties. Reduced levels may indicate increased cardiovascular risk or liver dysfunction.
Dynamics
Trend Interpretation
Rising Values
Progressively rising ApoA1 levels suggest improved cardiovascular health. Retest annually to monitor trends.
Falling Values
Progressively falling ApoA1 levels may indicate increased cardiovascular risk or liver dysfunction.
Re-test Interval
4 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Genetic factors
- Regular physical activity
- High HDL cholesterol levels
- Certain medications (e.g., statins)
Cause
Low Levels
- Liver disease
- Chronic inflammation
- Malnutrition
- Metabolic syndrome
Protocol
How to Optimize
Lever
Nutrition
- Increase intake of omega-3 fatty acids
- Consume a diet rich in fruits and vegetables
- Limit saturated fat intake
Lever
Supplementation
- Niacin
- Fish oil
Note:
Consult a healthcare provider before starting any supplementation, especially if you have underlying health conditions.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Annually for cardiovascular risk assessment
Interfering Factors
- Acute illness
- Chronic inflammation
Related Peptides & Hormones
Hdl Cholesterol
hormone or peptideCorrelated with
Open Research Questions
Current research suggests that reference ranges for apolipoprotein A1 (ApoA1) and its optimal targets in various clinical contexts, such as liver disease and cryoglobulinemia, remain debated. Researchers have not yet established the specific confounders affecting ApoA1 levels, particularly in non-fasting versus fasting states. Additionally, unanswered clinical questions include the precise role of ApoA1 in immune function and its potential as a therapeutic target in atherosclerosis and other lipid metabolism disorders.
31 Research Publications
1,157
Total Citations
20
Human/RCT
7.4
Avg. Influence
2025
Latest
Sort
Filter
01Top
#01
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.
HumanInfluence33.0
819
Researchers found that fasting status does not significantly affect the concentrations of apolipoprotein A1 and other lipid profile components. The study recommends using non-fasting lipid profiles for routine assessments, which can improve patient compliance without compromising the accuracy of cardiovascular risk predictions.
02Top
#02
Blood-based biomarkers for Parkinson's disease.
ReviewInfluence1.0
141
Researchers discussed the potential of Apolipoprotein A1 (APOA1) as a blood-based biomarker for Parkinson's disease, among other candidates. They highlighted the challenges and advancements in identifying effective biomarkers from blood samples.
03Top
#03
Apolipoprotein A1 and B.
ReviewInfluence1.0
49
This article reviewed the superiority of apolipoproteins A1 and B over traditional cholesterol measures in assessing vascular disease risk. Researchers highlighted the importance of these biomarkers in laboratory practices and their relevance in monitoring lipid-lowering therapies.
04
#04
Serum apolipoprotein A-I depletion is causative to silica nanoparticles-induced cardiovascular damage.
Animal
48
Researchers found that silica nanoparticles can deplete Apolipoprotein A1 (ApoA1) from the bloodstream, leading to cardiovascular damage. The study suggests that maintaining ApoA1 levels may be important for mitigating the toxic effects of nanoparticle exposure.
05
#05
HDLs and the pathogenesis of atherosclerosis.
Schwertani Adel, et al. · Current opinion in cardiology · 2018
Review
18
This review explored the role of HDL and apolipoprotein A1 in atherosclerosis. Researchers found that HDL's protective functions can be compromised in disease states, suggesting that changes in Apo A-I may contribute to the progression of cardiovascular diseases.
Key findings
- 01Researchers observed that HDL cholesterol levels are not effective therapeutic targets for preventing heart disease.
- 02They found that HDL performs various protective functions against atherosclerosis that are independent of cholesterol levels.
- 03The study identified a protein, desmocollin 1, that may hinder HDL's beneficial roles in heart health.
06
#06
HDL Structure.
Review
17
This study examined the structure and function of high-density lipoprotein (HDL), highlighting the role of apolipoprotein A1 (Apo A-I) as a major component. Researchers found that HDL is involved in various physiological processes and that its structure can change under different conditions, affecting its function in lipid metabolism and immune response.
07
#07
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype.
Human
11
Researchers found that higher levels of Apolipoprotein A1 (ApoA1) and HDL cholesterol were associated with improved responses to immunotherapy in nasopharyngeal carcinoma patients. The study suggested that ApoA1 mimetics could enhance therapeutic outcomes by modulating macrophage polarization.
08
#08
ApoA1/HDL and sepsis-associated vascular endothelial injury: a narrative review.
Guo Kailin, et al. · Critical care (London, England) · 2025
ReviewInfluence1.0
9
This review focused on the role of apolipoprotein A1 in sepsis-related vascular injury. Researchers found that decreased levels of Apo A-I are linked to endothelial damage, suggesting its potential as a therapeutic target for improving vascular health in sepsis.
Key findings
- 01Researchers observed a strong connection between decreased ApoA1/HDL levels and endothelial damage during infections.
- 02They identified three protective mechanisms of ApoA1: reducing inflammation, maintaining blood vessel integrity, and restoring blood flow.
- 03The review suggests that therapies based on ApoA1, such as mimetic peptides and recombinant HDL, could be promising for treating sepsis.
09
#09
Association between serum apolipoprotein B and atrial fibrillation: a case-control study.
Human
8
This study examined the association between Apolipoprotein B (ApoB) levels and atrial fibrillation (AF). Researchers found that lower ApoB levels were linked to a protective effect against AF in both men and women, indicating its potential as a biomarker.
10
#10
APOA1 mRNA and serum APOA1 protein as diagnostic and prognostic biomarkers in gastric cancer.
Human
8
Researchers explored the prognostic value of Apolipoprotein A1 (APOA1) in gastric cancer, finding that lower levels were linked to poor prognosis. The study suggests that APOA1 could serve as a diagnostic and prognostic biomarker in managing gastric cancer.
Clinical Trials (2)
2
Total Trials
2,050
Total Enrolled
Effects of 10 Weeks of Lifestyle Coaching on Cardiometabolic Risk Factors, Workability and Subjective Wellbeing
NCT04633876UNKNOWN
Sponsor
Aava Medical
Enrollment
2,000
Started
2020
Primary outcome
ApoB/ApoA1
Work Related StressMetabolic SyndromeLipid Metabolism DisordersLifestyle Risk ReductionBurnout
Resveratrol and Serum Apo A-I
NCT01364961COMPLETED
Sponsor
Maastricht University Medical Center
Enrollment
50
Started
2011
Primary outcome
ApoA-I level
Dyslipidemia
Publication Trend
Research publications about Apolipoprotein A1 over time
10totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer